These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6800852)

  • 21. Inhibitory effects of a single intranasal administration of [D-Ser(TBU)6, des-Gly-NH210]LHRH ethylamide, a potent LHRH agonist, on serum steroid levels in normal adult men.
    Bélanger A; Labrie F; Lemay A; Caron S; Raynaud JP
    J Steroid Biochem; 1980 Feb; 13(2):123-6. PubMed ID: 6770199
    [No Abstract]   [Full Text] [Related]  

  • 22. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration.
    Tolis G; Faure N; Koutsilieris M; Lemay A; Klioze S; Yakabow A; Fazekas AT
    J Steroid Biochem; 1983 Jul; 19(1C):995-8. PubMed ID: 6411994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Lemay A; Quesnel G
    Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hypogonadotropic hypogonadal male patients with the luteinizing hormone-relasing hormone (LH-RH) anolog D-Ser(TBU)6 EA10 LH-RH: transient disappearance of gonadotropin stimulation.
    Morel Y; Fournier M; Mazenod B; Tourniaire J; Mornex R
    Fertil Steril; 1982 Jul; 38(1):85-91. PubMed ID: 6807722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I; Venho P; Jacobi G; Rannikko S
    J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Faure N; Lemay A
    Clin Endocrinol (Oxf); 1987 Dec; 27(6):703-13. PubMed ID: 3138052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6509-12. PubMed ID: 6458815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic effects of the stimulatory luteinizing hormone-releasing hormone analogue D-Ser (TBU) 6-EA 10-LRH on the gonadotrophin and gonadal steroid secretion in women with amenorrhoea.
    Skarin G; Nillius SJ; Wide L
    Ups J Med Sci; 1980; 85(2):103-12. PubMed ID: 6787767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Monfette G; Laberge JG; Emond JP; Raynaud JP; Husson JM; Fazekas AT
    J Steroid Biochem; 1983 Jul; 19(1C):999-1007. PubMed ID: 6411995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The sustained release of LH X RH agonist from LH X RH agonist-polymer composite in patients with prostatic cancer.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetu I; Yamazaki I; Suzuki K
    Prostate; 1986; 8(4):325-32. PubMed ID: 3086853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luteolytic activity of LHRH and [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide: a new and physiological approach to contraception in women.
    Lemay A; Labrie F; Raynaud JP
    Int J Fertil; 1980; 25(3):203-12. PubMed ID: 6108931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recovery of gonadal functions in the adult male rat following cessation of five-month daily treatment with an LHRH agonist.
    Lefebvre FA; Bélanger A; Pelletier G; Labrie F
    J Androl; 1984; 5(3):181-92. PubMed ID: 6086556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of a direct inhibitory effect of the gonadotropin-releasing hormone (GnRH) agonist D-Ser (TBU)6, des-Gly-NH2(10) GnRH ethylamide (Buserelin) on testicular steroidogenesis in men.
    Schaison G; Brailly S; Vuagnat P; Bouchard P; Milgrom E
    J Clin Endocrinol Metab; 1984 May; 58(5):885-8. PubMed ID: 6423662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gonadotropin and gonadal steroid release in response to a gonadotropin-releasing hormone agonist in Gqalpha and G11alpha knockout mice.
    Stanislaus D; Janovick JA; Ji T; Wilkie TM; Offermanns S; Conn PM
    Endocrinology; 1998 Jun; 139(6):2710-7. PubMed ID: 9607776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
    Bergquist C; Nillius SJ; Wide L; Lindgren A
    Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer.
    Nicholson RI; Walker KJ; Turkes A; Turkes AO; Dyas J; Blamey RW; Campbell FC; Robinson MR; Griffiths K
    J Steroid Biochem; 1984 Jan; 20(1):129-35. PubMed ID: 6231416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
    Wenderoth UK; Jacobi GH
    Prog Clin Biol Res; 1985; 185A():297-305. PubMed ID: 3162176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.